home All News open_in_new Full Article

Ozempic maker Novo Nordisk cuts sales and profit forecasts again

Downgrade comes as Danish company continues to lose ground to Mounjaro firm Eli Lilly in weight-loss drug marketThe maker of Ozempic and Wegovy has cut its sales and profit forecasts as it continues to fall behind in the competitive market for obesity and diabetes treatments.Novo Nordisk’s chief executive, Mike Doustdar, who took the reins in August, said the reduced guidance was because of “the lower growth expectations for our GLP-1 treatments”. Continue reading...


today 3 w. ago attach_file Economics

attach_file Economics
attach_file Economics
attach_file Economics
attach_file Events
attach_file Events
attach_file Events
attach_file Science
attach_file Events
attach_file Economics
attach_file Politics
attach_file Economics
attach_file Politics
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Events
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Politics


ID: 2865676955
Add Watch Country

arrow_drop_down